Connect your AI

Repligen RGEN Short- term Investments

Short- term Investments at other companies

Apogee Therapeutics, Inc.APGE

——

Other financials

Income statement

Revenue$194.3M+14.8%

Gross profit$108.3M+18.5%

Operating income$15.9M+142%

Net income$8.3M+42.9%

EPS (diluted)$0.15+50.0%

Balance sheet

Cash & equivalents$582.7M-16.4%

Total debt$687.6M+346%

Total equity$2.1B+6.0%

Total assets$2.9B+2.8%

Cash flow

Operating cash flow$28.3M+88.6%

CapEx$4.7M+32.2%

Free cash flow$23.6M+106%

Valuation

Market cap$7.45B-7.1%

Enterprise value$7.55B+2.1%

P/E144.9×—

P/S10.1×-0.1×

Profitability

Gross margin49.5%+2.7pp

Operating margin1.5%-14.0pp

Net margin17.1%-3.7pp

FCF margin21.2%+6.1pp

Returns & leverage

Return on equity2.5%+1.9pp

Debt / equity0.3×+0.2×

Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Repligen's short- term investments?: Repligen (RGEN) reported short- term investments of $201.88M in Q1 2026.